<p>Kestra Medical Technologies, Ltd.（NASDAQ:KMTS - 獲取免費報告）的股票在週五下跌了 7.2%，原因是高盛集團將該股票的目標價從 22.00 美元下調至 17.00 美元。高盛集團目前對該股票的評級為中性。Kestra Medical Technologies 的股價最低曾達到 18.05 美元，最後交易價為 17.8650 美元。在交易過程中，約有 82,926 股易手，較平均每日成交量 346,349 股下降了 76%。該股票之前的收盤價為 19.25 美元。</p>
<p>其他分析師也對該股票發佈了研究報告。BTIG Research 在週二的研究報告中重申了對 Kestra Medical Technologies 的 “買入” 評級，並設定了 32.00 美元的目標價。Stifel Nicolaus 在 12 月 12 日（週五）的研究報告中設定了 30.00 美元的目標價。Piper Sandler 在 12 月 12 日（週五）的研究報告中將 Kestra Medical Technologies 的目標價從 27.00 美元上調至 30.00 美元，並給予該公司 “超配” 評級。Wells Fargo &amp; Company 在 12 月 12 日（週五）的研究報告中將 Kestra Medical Technologies 的目標價從 27.00 美元上調至 28.00 美元，並給予該公司 “超配” 評級。最後，Weiss Ratings 在 3 月 23 日（週一）的研究報告中重申了對 Kestra Medical Technologies 的 “賣出（d-）” 評級。三位分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，平均目標價為 27.40 美元。</p>
<p><strong>查看我們最新的 KMTS 股票報告</strong></p>
<h2>Kestra Medical Technologies 的內部活動</h2>
<p>在相關消息中，內部人士 Brian Daniel Webster 在 3 月 17 日（週二）出售了 15,000 股該股票。股票以平均價格 20.27 美元出售，總價值為 304,050.00 美元。交易完成後，該內部人士在公司持有 364,786 股，價值 7,394,212.22 美元。這代表其持股比例下降了 3.95%。該出售在向 SEC 的備案中披露，相關文件可通過此鏈接獲取。內部人士在過去三個月內共出售了價值 1,030,050 美元的 45,000 股公司股票。目前，3.60% 的股票由公司內部人士持有。</p>
<h2>對 Kestra Medical Technologies 的對沖基金看法</h2>
<p>機構投資者和對沖基金最近買入和賣出了該股票的股份。Farther Finance Advisors LLC 在第四季度購買了 Kestra Medical Technologies 的新股份，價值 31,000 美元。Russell Investments Group Ltd.在第四季度將其在 Kestra Medical Technologies 的持股增加了 43.5%。Russell Investments Group Ltd.現在持有該公司 1,563 股股票，價值 41,000 美元，此前在該期間又購買了 474 股。China Universal Asset Management Co. Ltd.在第三季度購買了 Kestra Medical Technologies 的新股份，價值約 48,000 美元。BNP Paribas Financial Markets 在第三季度將其在 Kestra Medical Technologies 的股份增加了 148.9%。BNP Paribas Financial Markets 現在持有該公司 2,738 股股票，價值 65,000 美元，此前在上個季度又購買了 1,638 股。最後，Daiwa Securities Group Inc.在第四季度購買了 Kestra Medical Technologies 的新股份，價值約 72,000 美元。</p>
<h2>Kestra Medical Technologies 股票下跌 7.0%</h2>
<p>該公司的 50 日簡單移動平均線為 22.79 美元，200 日簡單移動平均線為 24.48 美元。該公司的速動比率為 7.32，流動比率為 7.32，債務與股本比率為 0.15。該公司的市值為 10.4 億美元，市盈率為-4.52。</p>
<p>Kestra Medical Technologies（NASDAQ:KMTS - 獲取免費報告）在 3 月 17 日（週二）發佈了季度財報。該公司報告季度每股收益為（0.61 美元），低於分析師一致預期的（0.60 美元）0.01 美元。Kestra Medical Technologies 的股本回報率為-65.49%，淨利潤率為-171.87%。該公司在本季度的收入為 2455 萬美元。Kestra Medical Technologies 的季度收入同比增長 62.7%。</p>
<h2>Kestra Medical Technologies 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>我們是一家商業階段的可穿戴醫療設備和數字醫療公司，專注於通過直觀、智能和互聯的監測和治療干預技術來改善心血管疾病患者的結果。我們開發並商業化了我們的心臟恢復系統平台，這是一個綜合且先進的系統，將監測、治療、數字健康和患者支持服務整合為一個統一的解決方案。我們心臟恢復系統平台的基石是 ASSURE WCD，這是一種下一代可穿戴心臟復律除顫器（“WCD”），用於保護處於突發心臟驟停（“SCA”）高風險的患者，這是一種公共衞生問題，約佔美國所有心血管死亡的 50%。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Kestra Medical Technologies 更具吸引力</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Kestra Medical Technologies 嗎？</h2>
<p>在考慮 Kestra Medical Technologies 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Kestra Medical Technologies 並不在名單上。</p>
<p>雖然 Kestra Medical Technologies 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

標普健康醫療設備 ETF - SPDR

美國醫藥設備 ETF - iShares

KMTS

<p>Kestra Medical Technologies（納斯達克代碼：KMTS）的股價下跌了 7.2%，原因是高盛將其評級下調，並將目標價從 22.00 美元下調至 17.00 美元。該股最低交易價為 18.05 美元，交易量顯著下降。其他分析師的評級則各有不同，BTIG Research 維持 “買入” 評級，目標價為 32.00 美元。儘管公司報告的季度每股收益為（0.61 美元），未能達到預期，但其營收同比增長了 62.7%。Kestra 專注於心血管疾病管理的可穿戴醫療設備</p>

<p>Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) were down 7.2% on Friday after The Goldman Sachs Group lowered their price target on the stock from $22.00 to $17.00. The Goldman Sachs Group currently has a neutral rating on the stock. Kestra Medical Technologies traded as low as $18.05 and last traded at $17.8650. Approximately 82,926 shares changed hands during trading, a decline of 76% from the average daily volume of 346,349 shares. The stock had previously closed at $19.25.</p>
<div class="lb-trans"><p>Kestra Medical Technologies, Ltd.（NASDAQ:KMTS - 獲取免費報告）的股票在週五下跌了 7.2%，原因是高盛集團將該股票的目標價從 22.00 美元下調至 17.00 美元。高盛集團目前對該股票的評級為中性。Kestra Medical Technologies 的股價最低曾達到 18.05 美元，最後交易價為 17.8650 美元。在交易過程中，約有 82,926 股易手，較平均每日成交量 346,349 股下降了 76%。該股票之前的收盤價為 19.25 美元。</p>
</div><p>Other analysts have also issued research reports about the stock. BTIG Research reiterated a &#34;buy&#34; rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research note on Tuesday. Stifel Nicolaus set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Friday, December 12th. Piper Sandler boosted their target price on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, December 12th. Wells Fargo &amp; Company boosted their target price on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, December 12th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Kestra Medical Technologies in a research note on Monday, March 23rd. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of &#34;Hold&#34; and an average price target of $27.40.</p>
<div class="lb-trans"><p>其他分析師也對該股票發佈了研究報告。BTIG Research 在週二的研究報告中重申了對 Kestra Medical Technologies 的 “買入” 評級，並設定了 32.00 美元的目標價。Stifel Nicolaus 在 12 月 12 日（週五）的研究報告中設定了 30.00 美元的目標價。Piper Sandler 在 12 月 12 日（週五）的研究報告中將 Kestra Medical Technologies 的目標價從 27.00 美元上調至 30.00 美元，並給予該公司 “超配” 評級。Wells Fargo &amp; Company 在 12 月 12 日（週五）的研究報告中將 Kestra Medical Technologies 的目標價從 27.00 美元上調至 28.00 美元，並給予該公司 “超配” 評級。最後，Weiss Ratings 在 3 月 23 日（週一）的研究報告中重申了對 Kestra Medical Technologies 的 “賣出（d-）” 評級。三位分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，平均目標價為 27.40 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on KMTS</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 KMTS 股票報告</strong></p>
</div><h2>Insider Activity at Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 的內部活動</h2>
</div><p>In related news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $20.27, for a total value of $304,050.00. Following the completion of the transaction, the insider owned 364,786 shares in the company, valued at $7,394,212.22. This represents a 3.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 45,000 shares of company stock worth $1,030,050 in the last three months. 3.60% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Brian Daniel Webster 在 3 月 17 日（週二）出售了 15,000 股該股票。股票以平均價格 20.27 美元出售，總價值為 304,050.00 美元。交易完成後，該內部人士在公司持有 364,786 股，價值 7,394,212.22 美元。這代表其持股比例下降了 3.95%。該出售在向 SEC 的備案中披露，相關文件可通過此鏈接獲取。內部人士在過去三個月內共出售了價值 1,030,050 美元的 45,000 股公司股票。目前，3.60% 的股票由公司內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Kestra Medical Technologies</h2>
<div class="lb-trans"><h2>對 Kestra Medical Technologies 的對沖基金看法</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC purchased a new stake in shares of Kestra Medical Technologies during the fourth quarter valued at $31,000. Russell Investments Group Ltd. raised its holdings in Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock worth $41,000 after buying an additional 474 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Kestra Medical Technologies during the third quarter valued at about $48,000. BNP Paribas Financial Markets lifted its stake in Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company's stock valued at $65,000 after buying an additional 1,638 shares in the last quarter. Finally, Daiwa Securities Group Inc. purchased a new stake in Kestra Medical Technologies during the fourth quarter valued at about $72,000.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近買入和賣出了該股票的股份。Farther Finance Advisors LLC 在第四季度購買了 Kestra Medical Technologies 的新股份，價值 31,000 美元。Russell Investments Group Ltd.在第四季度將其在 Kestra Medical Technologies 的持股增加了 43.5%。Russell Investments Group Ltd.現在持有該公司 1,563 股股票，價值 41,000 美元，此前在該期間又購買了 474 股。China Universal Asset Management Co. Ltd.在第三季度購買了 Kestra Medical Technologies 的新股份，價值約 48,000 美元。BNP Paribas Financial Markets 在第三季度將其在 Kestra Medical Technologies 的股份增加了 148.9%。BNP Paribas Financial Markets 現在持有該公司 2,738 股股票，價值 65,000 美元，此前在上個季度又購買了 1,638 股。最後，Daiwa Securities Group Inc.在第四季度購買了 Kestra Medical Technologies 的新股份，價值約 72,000 美元。</p>
</div><h2>Kestra Medical Technologies Stock Down 7.0%</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 股票下跌 7.0%</h2>
</div><p>The business's 50 day simple moving average is $22.79 and its 200 day simple moving average is $24.48. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.04 billion and a PE ratio of -4.52.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為 22.79 美元，200 日簡單移動平均線為 24.48 美元。該公司的速動比率為 7.32，流動比率為 7.32，債務與股本比率為 0.15。該公司的市值為 10.4 億美元，市盈率為-4.52。</p>
</div><p>Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The firm had revenue of $24.55 million during the quarter. Kestra Medical Technologies's revenue for the quarter was up 62.7% on a year-over-year basis.</p>
<div class="lb-trans"><p>Kestra Medical Technologies（NASDAQ:KMTS - 獲取免費報告）在 3 月 17 日（週二）發佈了季度財報。該公司報告季度每股收益為（0.61 美元），低於分析師一致預期的（0.60 美元）0.01 美元。Kestra Medical Technologies 的股本回報率為-65.49%，淨利潤率為-171.87%。該公司在本季度的收入為 2455 萬美元。Kestra Medical Technologies 的季度收入同比增長 62.7%。</p>
</div><h2>Kestra Medical Technologies Company Profile</h2>
<div class="lb-trans"><h2>Kestra Medical Technologies 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.</p>
<div class="lb-trans"><p>我們是一家商業階段的可穿戴醫療設備和數字醫療公司，專注於通過直觀、智能和互聯的監測和治療干預技術來改善心血管疾病患者的結果。我們開發並商業化了我們的心臟恢復系統平台，這是一個綜合且先進的系統，將監測、治療、數字健康和患者支持服務整合為一個統一的解決方案。我們心臟恢復系統平台的基石是 ASSURE WCD，這是一種下一代可穿戴心臟復律除顫器（“WCD”），用於保護處於突發心臟驟停（“SCA”）高風險的患者，這是一種公共衞生問題，約佔美國所有心血管死亡的 50%。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Kestra Medical Technologies</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Kestra Medical Technologies 更具吸引力</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kestra Medical Technologies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Kestra Medical Technologies 嗎？</h2>
</div><p>Before you consider Kestra Medical Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Kestra Medical Technologies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Kestra Medical Technologies 並不在名單上。</p>
</div><p>While Kestra Medical Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Kestra Medical Technologies 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Kestra Medical Technologies (NASDAQ:KMTS) 的股票價格因分析師的評級下調而下跌了 7.2%